The majority of cases in NSCLC include a subset of two to seven percent of patients exhibiting gene rearrangements of the ALK gene or chromosomal fusions of ALK with echinoderm microtubule-associated protein-like 4 (EML4) [55,56]. This evidence concerns the gene ALK and non-small cell lung carcinoma.